Immunovative Inc. Appoints Stella M. Sung, Ph.D. as First Member of Newly Established Medical Advisory Board

Immunovative Inc. Appoints Stella M. Sung, Ph.D. as First Member of Newly Established Medical Advisory Board

LOS ANGELES, CA--(Marketwire - March 15, 2013) - Immunovative Inc. (OTCQB: IMUN) or ("The Company") has today announced the appointment of Stella M. Sung, Ph.D. ("Dr. Sung") as the first member of the Company's newly established medical advisory board. As the Company continues to evaluate potentially lucrative opportunities in the biotech space, the advice of highly qualified and experienced individuals is of great importance. The Company will work diligently to attract additional members to its medical advisory board and benefit from both their industry relationships and rolodexes.

IMUN CEO Seth M. Shaw commented, "The Company is pleased to have attracted such an outstanding candidate to its newly formed medical advisory board. Management will continue to prioritize the assembly of its medical advisory board with individuals who have built impressive resumes and successful careers."

Newly appointed medical advisory board member, Dr. Stella Sung stated, "I am pleased to join the newly formed medical advisory board of the Company. The company is evaluating a number of promising biotechnology and healthcare opportunities with the potential to create significant shareholder value in the relatively near term. As a long-time venture capitalist, I enjoy sourcing innovative life science investment opportunities, assessing their scientific merit, and building companies."

Please see below Bio for Dr. Stella M. Sung:

Dr. Stella M. Sung brings almost 20 years of leadership experience in the healthcare sector as both a senior operating executive and an early stage life science venture capitalist. Dr. Sung is currently Business Development Officer of Avita Medical, a public regenerative medicine company, and Managing Director of Pearl Street Venture Fund, a life science venture fund. She previously held the position of Chief Business Officer of Cylene Pharmaceuticals, a venture-backed oncology company. Dr. Sung has served as a Managing Director or General Partner for several life science venture firms, including Coastview Capital (founded by former Amgen CEO Gordon Binder) and Oxford Bioscience Partners. She has led venture rounds of financing for seven transactions, co-founded two biotechnology companies, served on 7 Boards of Directors and served as Chairman of the Board for four biotechnology companies. Previously, she focused on life science and health care investments at Advent International, a global private equity firm that has raised over $6 billion in cumulative capital to date. Dr. Sung received her B.S. in chemistry from The Ohio State University and her Ph.D. in chemistry from Harvard University, where she was a National Science Foundation Pre-Doctoral Fellow. She earned her Harvard Ph.D. under the guidance of Professor Dudley Herschbach, the 1986 Nobel Laureate in Chemistry. (http://www.psvf.com/stella-m-sung.asp)

About Immunovative Inc.

Immunovative's focus is to evaluate potential opportunities in the biotechnology and/or medical device industry, however it will consider other potential business sectors if deemed in the best interest of shareholders. Additionally on March 4, 2013, the Company announced that it filed for a name and symbol change, such that the Company has changed its name to Tauriga Sciences Inc. and is awaiting its new trading symbol.

Suggested Articles

Astellas will develop Frequency's hearing loss drug outside the U.S. in exchange for $80 million upfront and the promise of $545 million down the line.

Inovio Pharmaceuticals is cutting 28% of its workforce and swinging the ax to a bladder cancer test.

The agency was less likely to go against a recommendation when the panellists were united in their opinion.